Long-term follow-up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer
M. J. Piccart, K. Bertelsen, G. Stuart, J. Cassidy, C. Mangioni, E. Simonsen, K. James, S. Kaye, I. Vergote, R. Blom, R. Grimshaw, R. Atkinson, K. Swenerton, C. Trope, M. Nardi, J. Kaern, S. Tumolo, P. Timmers, J.-A. Roy, F. Lhoas, B. Lidvall, M. Bacon, A. Birt, J. Andersen, B. Zee, J. Paul, S. Pecorelli, B. Baron, W. Mcguire
International Journal of Gynecologic Cancer Oct 2003, 13 (Suppl 2) 144-148; DOI: 10.1136/ijgc-00009577-200311001-00003
